Healthcare / Medical DistributionBSE
$194.55
+8.80 (+4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-25.0M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
62.6x
↑EV/EBITDA
18.4x
↑ROE
19.8%
↑Gross Margin
54.1%
↑Debt/Equity
0.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+49.6%
FCF CAGR
—
FCF margin
-19.4%
FCF / Net income
-1.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $465.7M · net income $46.2M · FCF $-90.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $465.7M | $465.7M | $245.6M | $178.6M | $139.0M |
| Net Income | $46.2M | $46.2M | $31.0M | $8.0M | $1.9M |
| EBITDA | $75.8M | $75.8M | $49.3M | $14.9M | $5.7M |
| EPS | — | — | 4.52 | 1.16 | 0.28 |
| Gross Margin | 54.1% | 54.1% | 63.2% | 46.4% | 42.2% |
| Operating Margin | 15.1% | 15.1% | 18.7% | 7.5% | 3.2% |
| Net Margin | 9.9% | 9.9% | 12.6% | 4.5% | 1.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.31 | 0.31 | 1.49 | 3.00 | 2.28 |
| Current Ratio | 1.82 | 1.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-90.5M | $-90.5M | $-24.6M | $-25.0M | $-5.3M |
| Returns | |||||
| ROE | 19.8% | 19.8% | 44.5% | 45.2% | 20.1% |
| Valuation | |||||
| P/E | 62.56 | 62.56 | — | — | — |
| EV/EBITDA | 18.42 | 18.42 | — | — | — |
| P/B | 5.72 | 5.72 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 89.7% | 89.7% | 37.5% | 28.5% | — |
| EPS Growth | — | — | 288.4% | 310.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+446.0%
Start / end P/E
n/dx → n/dx
EPS bridge
4.52 → n/d
Residual
+446.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.